BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $826

BTIG analyst Kambiz Yazdi has maintained a Buy rating on Praxis Precision Medicine (NASDAQ: PRAX) and increased the price target from $810 to $826. This adjustment reflects a positive outlook for the company's stock performance.